Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2015 1
2016 1
2017 1
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Effects of Serelaxin in Patients with Acute Heart Failure.
Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Voors AA, Adams KF, Anker SD, Arias-Mendoza A, Avendaño P, Bacal F, Böhm M, Bortman G, Cleland JGF, Cohen-Solal A, Crespo-Leiro MG, Dorobantu M, Echeverría LE, Ferrari R, Goland S, Goncalvesová E, Goudev A, Køber L, Lema-Osores J, Levy PD, McDonald K, Manga P, Merkely B, Mueller C, Pieske B, Silva-Cardoso J, Špinar J, Squire I, Stępińska J, Van Mieghem W, von Lewinski D, Wikström G, Yilmaz MB, Hagner N, Holbro T, Hua TA, Sabarwal SV, Severin T, Szecsödy P, Gimpelewicz C; RELAX-AHF-2 Committees Investigators. Metra M, et al. N Engl J Med. 2019 Aug 22;381(8):716-726. doi: 10.1056/NEJMoa1801291. N Engl J Med. 2019. PMID: 31433919 Free article. Clinical Trial.
Previous studies have suggested that treatment with serelaxin may result in relief of symptoms and in better outcomes in patients with acute heart failure. ...The incidence of adverse events was similar in the two groups. CONCLUSIONS: In this …
Previous studies have suggested that treatment with serelaxin may result in relief of symptoms and in better outcomes in patie …
Serelaxin and acute heart failure.
Tietjens J, Teerlink JR. Tietjens J, et al. Heart. 2016 Jan;102(2):95-9. doi: 10.1136/heartjnl-2014-306786. Epub 2015 Nov 24. Heart. 2016. PMID: 26603680 Review.
A 1161-patient, placebo-controlled Phase III trial, RELAX-AHF, demonstrated significant improvement in symptoms, reduced worsening of heart failure, decreased hospital length of stay and increased 180-day survival after index hospi …
A 1161-patient, placebo-controlled Phase III trial, RELAX-AHF, demonstrated significant improvement in sy …
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Teerlink JR, et al. Lancet. 2013 Jan 5;381(9860):29-39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7. Lancet. 2013. PMID: 23141816 Clinical Trial.
In a pilot study, serelaxin was safe and well tolerated with positive clinical outcome signals in patients with acute heart failure. ...METHODS: RELAX-AHF was an international, double-blind, placebo-controlled tria …
In a pilot study, serelaxin was safe and well tolerated with positive clinical outcome signals in patients with acute …
Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies).
Davison BA, Takagi K, Edwards C, Adams KF Jr, Butler J, Collins SP, Dorobantu MI, Ezekowitz JA, Filippatos G, Greenberg BH, Levy PD, Masip J, Metra M, Pang PS, Ponikowski P, Severin TM, Teerlink JR, Teichman SL, Voors AA, Werdan K, Cotter G. Davison BA, et al. Am J Cardiol. 2022 Oct 1;180:72-80. doi: 10.1016/j.amjcard.2022.06.037. Epub 2022 Aug 4. Am J Cardiol. 2022. PMID: 35933224 Clinical Trial.
Previous studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) is a novel yet readily evaluable inflammatory biomarker that may be useful for determining cardiovascular prognosis during acute episodes. The study investigated the role of NLR in predicting car …
Previous studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) is a novel yet readily evaluable inflammatory biomarker that m …
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
Teerlink JR, Voors AA, Ponikowski P, Pang PS, Greenberg BH, Filippatos G, Felker GM, Davison BA, Cotter G, Gimpelewicz C, Boer-Martins L, Wernsing M, Hua TA, Severin T, Metra M. Teerlink JR, et al. Eur J Heart Fail. 2017 Jun;19(6):800-809. doi: 10.1002/ejhf.830. Epub 2017 Apr 28. Eur J Heart Fail. 2017. PMID: 28452195 Free PMC article. Clinical Trial.
In the phase 3 RELAX-AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day 5 in patients admitted for AHF. ...RELAX-AHF-2 ( ClinicalTrials.gov NCT01870778) is designed to confirm serelaxin's effect on thes …
In the phase 3 RELAX-AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day 5 in patien …